Physician profile
Lora M Collier
NPI 1154371524
$2,912.30
in general payments reported to CMS, 2019-2025
29 companies · $688 in 2025
The $688 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $337 · 2021: $56.44 · 2022: $547 · 2023: $568 · 2024: $500 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,755.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $678.15 | 2019-2025 | Farxiga, Airsupra, Bevespi Aerosphere |
| Amgen INC. | $384.93 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $243.15 | 2021-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $225.02 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $206.39 | 2022-2025 | |
| Glaxosmithkline, LLC. | $153.22 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Teva Pharmaceuticals USA, INC. | $144.14 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.01 | 2023-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $94.05 | 2019-2020 | |
| Pfizer INC. | $87.83 | 2019-2025 | |
| Lilly USA, LLC | $86.24 | 2022-2025 | Jardiance, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $60.87 | 2023-2024 | Trintellix, Glassia |
| Astellas Pharma US INC | $54.49 | 2025 | Veozah |
| Abbott Laboratories | $41.27 | 2022 | |
| Sanofi-Aventis U.S. LLC | $39.08 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $31.59 | 2019-2020 | |
| Verona Pharma, INC. | $29.28 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $28.39 | 2023 | |
| Merck Sharp & Dohme LLC | $27.76 | 2020 | |
| Exact Sciences Corporation | $24.93 | 2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $19.80 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $16.46 | 2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.31 | 2023 | Xifaxan |
| Dexcom, INC. | $15.05 | 2021 | |
| Sanofi Pasteur INC. | $14.89 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.99 | 2022 | |
| Alk-Abello, INC | $13.88 | 2024 | Odactra, Grastek, Ragwitek |
| Idorsia Pharmaceuticals US INC | $13.80 | 2023 | Quviviq |
| Eisai INC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lora Collier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.